The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb). The mAb targets G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM). … Read More
A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284. Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify… Read More
New molecular insights into cancer stem cells have highlighted their potential as therapeutic targets. In a recent study, researchers have revealed how transcription factors CDX1 and CDX2 suppress cancer cell stemness by blocking β-catenin’s ability to activate key genes like LGR5. Their findings showed that… Read More
Kathy Davy, President of Next-Generation Clinical Sequencing Division, Thermo Fisher Scientific, asks how clinical trials in cancer can be accelerated through the use of rapid next-generation sequencing (NGS) technology. Every cancer diagnosis marks the beginning of an urgent and often overwhelming journey for patients and their families. And in some… Read More
Dispatch Bio has officially launched with a stated mission to engineer a universal treatment across solid tumours. Immunotherapies have struggled to effectively treat solid tumours due to the lack of a tumour-specific target and the presence of an immune-suppressive tumour microenvironment. Dispatch’s Flare platform has been engineered to overcome these. Read More
Cancer is no longer seen as a simple disease of unchecked cell growth, but as a complex, adaptive ecosystem shaped by genetic mutations, immune evasion, and transcriptional plasticity that allow tumours to survive and evolve. Steve Pollard, CSO & Founder of Trogenix and Professor of Stem Cell and Cancer Biology,… Read More
Scientists have uncovered a protein that acts like a ‘suit of armour’ for cancer cells, shielding them from hostile environments and allowing one of the deadliest forms of skin cancer to spread through the body. A team of researchers from The Institute of Cancer Research, London, has identified that a… Read More
FUJIFILM Pharmaceuticals’ FF-10832—an investigational liposomal formulation of gemcitabine—has granted orphan drug designation for the treatment of biliary tract cancer (BTC) by the US Food and Drug Administration (FDA). FF-10832 is currently being evaluated in Phase IIa studies as monotherapy or in combination with pembrolizumab for the treatment of solid tumours… Read More
The European Commission has approved Tevimbra (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper… Read More
Cancer Research Horizons, the innovation arm of Cancer Research UK, announced the winners of its third Innovation and Entrepreneurship Awards during an awards ceremony at Merchant Taylors’ Hall, London. Dr Alessia Errico, Associate Director of Search and Evaluation at Cancer Research Horizons, said: “These remarkable innovators demonstrate the determination and… Read More
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment. According to the decision, this treatment should be followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery… Read More
For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues. Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed blood cell genomes from 23 patients of all ages who… Read More
The first patient has been dosed in a global multicentre clinical trial to evaluate ISM3412, a potentially best-in-class, MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumours. The Phase I study consists of two parts: dose escalation and dose selection optimisation, where participants will receive… Read More
Researchers from Japan have shown that benzaldehyde, a compound responsible for the aroma of almonds, halts the growth and spread of therapy-resistant pancreatic cancer. By preventing various signalling proteins and histone modifiers like Ser28-phosphorylated histone H3 (H3S28ph) from binding to 14-3-3ζ protein, the study has shown that benzaldehyde overcomes therapy… Read More
OS Therapies has shared positive clinical trial data updates from its Phase IIb clinical trial of immunotherapy candidate OST-HER2 in fully resected, lung metastatic osteosarcoma. The data were presented by Principal Investigator Dr Damon Reed at the MIB Factor Osteosarcoma Conference held in Salt Lake City, Utah… Read More
Techbio Tailor Bio has published a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types. The study, carried out in collaboration with the University of Cambridge and the Spanish National Cancer… Read More
